Medicine | Indication(s)* | Dose(s)* | Originator company | Expiry of term for base compound patent† | Target price per patient per year | |
---|---|---|---|---|---|---|
USA | EU | |||||
Imatinib (Glivec/Gleevec) | Chronic myeloid leukaemia | 400 mg QD | Novartis | 2015 | 2016 | $128–$216 |
Erlotinib (Tarceva) | Non-small cell lung cancer (locally advanced or metastatic) | 150 mg QD | Roche | 2018 | 2020 | $240 |
Sorafenib (Nexavar) | Renal cell carcinoma, Hepatocellular carcinoma | 400 mg BID | Bayer and Onyx Pharmaceuticals | 2020 | 2020 | $1450 |
Lapatinib (Tyverb/Tykerb) | Advanced breast cancer | 1500 mg QD | Novartis | 2020 | 2023 | $4020 |
*References in online supplementary appendix 1.
†References for patent expiry dates are given in online supplementary appendix 2 and assume no supplementary patent term extensions.
BID, two times a day; QD, daily; TKI, tyrosine kinase inhibitor.